How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: A survey

Journal of Rheumatology

Volumn 25, Issue 12, 1998, Pages 2331-2338

  Maetzel, Andreas ^a,e   Bombardier, Claire ^a,b   Strand, Vibeke ^c   Tugwell, Peter ^d   Wells, George ^d  

^a Arthritis and Immune Disorder Research Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c STANFORD UNIVERSITY   (United States)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e Princess Margaret Cancer Centre   (Canada)

Author keywords

Drug therapy; Rheumatoid arthritis

Indexed keywords

AURANOFIN; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTICLE; CANADA; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG CHOICE; GOLD THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT PLANNING; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANADA; DATA COLLECTION; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RHEUMATOLOGY; SULFASALAZINE; UNITED STATES;

EID: 0031798177     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wilke WS, Sweeney TJ, Calabrese LH. Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome [review]. Semin Arthritis Rheum 1993;23:26-41.
2. McCarty DJ. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians [editorial]. J Rheumatol 1990;17:1115-8.
3. Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22:836-43.
4. Collins D, Bellamy N, Camphell J. A Canadian survey of current methotrexate prescribing practices in rheumatoid arthritis. J Rheumatol 1994;21:1220-3.
5. Bellamy N, Brooks PM, Campbell J, Drane D, Dupen F. An Australian survey of current prescribing practices of methotrexate in rheumatoid arthritis. Aust NZ J Med 1994;24:214-6.
6. Criswell LA, Henke CJ. What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? J Rheumatol 1995;22:829-35.
7. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive stalls. J Rheumatol 1990;17: 994-1002.
8. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
9. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995;54: 708-12.
10. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice [published erratum appears in J Rheumatol 1992;19:1998]. J Rheumatol 1992;19:704-8.
11. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. New Engl J Med 1996;334:1287-91.
12. Jones TV, Gerrity MS, Earp J. Written case simulations: do they predict physicians' behavior? [see comments]. J Clin Epidemiol 1990;43:805-15.
13. Rethans JJ, van Boven CP. Simulated patients in general practice: a different look at the consultation. BMJ 1987;294:809-12.
14. Kirwan JR, Chaput de Saintonge DM, Joyce CR, Currey HL. Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of 'paper patients'. Ann Rheum Dis 1983;42:644-7.
15. Kirwan JR, Bellamy N, Condon H, Buchanan WW, Barnes CG. Judging "current disease activity" in rheumatoid arthritis - an international comparison. J Rheumatol 1983;10:901-5.
16. Holt WS Jr, Mazzuca SA. A written case simulation of osteoarthritis as a predictor of prescribing behavior among family practitioners. Acad Med 1992;67:414-5.
17. Wolfe F, Pincus T, Fries JF, US Inception Cohort Group. Use of second line "disease modifying" antirheumatic drugs within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under care of 142 US rheumatologists: an inception cohort study [abstract]. Arthritis Rheum 1997;40 Suppl:S218.
18. Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25.
19. Moreland LW, Kimberly RP, Alarcon GS. European and US rheumatologists agree in triple but not on double of single early DMARD choice for different types of RA [abstract]. Arthritis Rheum 1997;40:S218.
20. O'Dell JR, Rheumatoid Arthritis Investigational Network. Combination therapy for rheumatoid arthritis: Apparent universal acceptance [abstract]. Arthritis Rheum 1997;40 Suppl:S50.
21. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997;50:1129-36.